ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Lexicon Pharmaceuticals, Inc." (LXRX) Report Updated: Aug 18, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Lexicon Pharmaceuticals, Inc." (LXRX)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: ENTA, CBPO, DYAX, GNVC

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Lexicon Pharmaceuticals, Inc."© quotemedia

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of drug programs in various stages of clinical development include LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2, which is in Phase IIb clinical trials for the treatment of type 2 diabetes; LX1032, an inhibitor of tryptophan hydroxylase, is preparing for Phase III registrational trials to reduce peripheral serotonin production without affecting brain serotonin levels in patients with carcinoid syndrome, as well as initiated a Phase II proof-of-concept trial for patients with ulcerative colitis; and LX1033, a serotonin synthesis inhibitor that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company also develops LX2931, an inhibitor of sphingosine-1-phosphate lyase, which completed a Phase IIa clinical trials and conducting a dose-ranging study to explore higher doses as a treatment for rheumatoid arthritis and other autoimmune diseases; and LX7101, an orally-delivered small molecule compound that initiated a Phase I-II proof-of-concept study in glaucoma patients. It also has advanced small molecule compounds from various additional drug programs into various stages of preclinical development and research. The company has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Recent News: "Lexicon Pharmaceuticals, Inc."